Selective Strategy Could Lead to New Approaches Against Schizophrenia
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. Led by Stephen Traynelis, PhD, professor of pharmacology and ACTSI investigator, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others. The research was supported by several organizations including the Atlanta Clinical and Translational Science Institute. Read more…